Bristol-Myers Squibb News, Bristol-Myers Squibb Quote, BMY Quote

Bristol-Myers Squibb (NY:BMY) Delayed: 59.75 -0.82 (1.35%)

Prev. Close

$60.57

Today 6M 1Y 5Y

Open

$61.10

52 Wk High

$77.12

52 Wk Low

$49.03

Day High

$61.43

Day Low

$59.54

P/E

38.80

EPS

$1.54

Volume

13,778,562

Friends, Peers and Foes (?): BMS, PFE, AZN, MRK, ABBV (more...)

ALERTS | RSS

Oct 13, 2026 08:59 AM Bernstein SocGen on Bristol-Myers Squibb Co. (BMY): 'Stock remains constrained by questions & remaining catalyst pathway'
Oct 13, 2026 05:55 AM Bristol-Myers Squibb Co. (BMY) PT Lowered to $60 at Wells Fargo
Oct 12, 2026 07:27 AM Bristol Myers Squibb stock surges on dual phase 3 clinical trial successes
Oct 12, 2026 06:55 AM Bristol Myers Squibb's RYZ101 meets primary endpoint in phase 3 GEP-NET trial
Oct 12, 2026 06:55 AM Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
Oct 12, 2026 06:50 AM Bristol Myers Squibb lung fibrosis drug meets Phase 3 trial goal
Oct 12, 2026 06:50 AM Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Oct 8, 2026 07:12 AM Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Cantor Fitzgerald on Anticipated Milvexian Pressure
Oct 8, 2026 06:59 AM BMS drug Zenbexus cuts myeloma progression risk by 51% in trial
Oct 8, 2026 06:59 AM Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refr

Entities mentioned with BMY

View All Entities